Moleculin Biotech Inc (MBRX) Stock Analysis
Verdict: AVOID
High-volume speculative rally masks a terminal liquidity risk; MBRX faces an imminent cash-out date within fiscal 2026.
Investment score: 38/100
Analysis as of
Is Moleculin Biotech Inc stock worth reviewing? AI model thesis
Avoid due to extreme dilution risk and lack of cash runway.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
Moleculin Biotech Inc opportunities and risks
What speaks for MBRX
- Clinical Data Catalyst
What speaks against MBRX
- Severe Equity Dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MBRX | n/a | 0.0x | n/a | 0.0% | 0.0% | -127.5% |
| CLRB | n/a | 0.0x | n/a | 0.0% | 0.0% | -224.0% |
| ALLR | n/a | 60.0x | n/a | 107.5% | -3260.6% | -80.7% |
| ATOS | n/a | 0.0x | 0.4x | 0.0% | 0.0% | -195.9% |
| OTLC | 0.1x | 0.0x | 48.7x | 0.0% | 0.0% | -8.8% |
| GTBP | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -282.0% |
| Peer median | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -195.9% |
Frequently asked questions about Moleculin Biotech Inc (MBRX)
Is MBRX stock a good investment?
The cached TradeMates AI model rates Moleculin Biotech Inc as AVOID with an investment score of 38/100. Avoid due to extreme dilution risk and lack of cash runway. This is algorithmic model output, not personal investment advice.
Is MBRX stock a buy?
The TradeMates model verdict for MBRX is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.